Search | IOVS | ARVO Journals

Showing 1 – 17 of 17

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2019

Long-term follow up or macular neovascularization using optical coherence tomography angiography: Pro Re Nata versus Treat&Extend regimens

Pierre Sustronck; Alexandra Miere; Hassiba Oubraham; Eric H Souied

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):124. doi:

ARVO Annual Meeting Abstract July 2018

OCT Angiography in the diagnosis and follow-up of retinal arterial macroaneurysms

Polina Astroz; Alexandra Miere; francesca amoroso; Alexandre Pedinielli; Hassiba Oubraham; Farah Gherdaoui; Salomon Y Cohen; Giuseppe Querques; Eric H Souied

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3156. doi:

ARVO Annual Meeting Abstract June 2017

Switching to aflibercept from ranibizumab in choroidal neovascularization related to angioid streaks: a multicenter real life study

Rim Sekfali; gerard mimoun; Vittorio Capuano; Salomon Y Cohen; Camille JUNG; OUBRAHAM-MEBROUKINE Hassiba; Giuseppe Querques; Eric H SOUIED

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2308. doi:

ARVO Annual Meeting Abstract June 2017

Optical coherence tomography angiography visualizes morphological changes in choroidal neovascularization after anti-VEGF therapy: Monthly loading-phase versus Pro-Re-Nata regimen.

OUBRAHAM-MEBROUKINE Hassiba; Alexandra Miere; Francesca Amoroso; Salomon Y Cohen; Pauline BUTORI; polina astroz evtouchenko; Camille JUNG; Eric Souied; Oudy Semoun

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):381. doi:

ARVO Annual Meeting Abstract September 2016

Real Life Use of Aflibercept In FraNce: oBservatiOnal study in Wet AMD: the RAINBOW study

OUBRAHAM-MEBROUKINE Hassiba; Celine Faure; Florence Coscas; Thi Ha Chau Tran; Benedicte Briend-Joulain; Laurent Velasque; Isabelle Aubry; Michel Weber; Salomon Y Cohen

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):524. doi:

ARVO Annual Meeting Abstract September 2016

Ranibizumab in patients with neovascular age-related macular degeneration in real-world clinical settings in France: 1-year data from the LUMINOUS™ study

Vittorio Capuano; OUBRAHAM-MEBROUKINE Hassiba; Benjamin Wolff; Salomon Y Cohen; Catherine P Garcher; Jean-Francois Korobelnik; Ramin Tadayoni; Christian Delhay; Audrey Derveloy; Eric H Souied

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):534. doi:

ARVO Annual Meeting Abstract June 2015

Early and delayed visual acuity responders to ranibizumab in patients with neovascular age-related macular degeneration: a retrospective pooled analysis from the real-world LUMIERE and TWIN studies

jean paul bellamy; Gérard Mimoun; Eric H Souied; Hassiba Oubraham; Catherine Français; Franck Rumen; Marie-Laure Lelez; Elisabeth Hermouet; Laetitia Finzi; Salomon Y Cohen

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2823. doi:

ARVO Annual Meeting Abstract June 2015

Short-term results of the switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration

Despréaux Raphaëlle; Salomon Y Cohen; Oudy Semoun; Olivia Zambrowski; Camille Yung; Hassiba Oubraham; Eric H Souied

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4586. doi:

ARVO Annual Meeting Abstract June 2015

Anatomic and functional results of Vascularized Pigment Epithelial Detachment treatment with ranibizumab ( V-PED): One year follow-up of visual and anatomical outcomes

Hassiba Oubraham Mebroukine; Olivier Chevreaud; Farah Gherdaoui; Camille Jung; Eric H Souied

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5359. doi:

ARVO Annual Meeting Abstract June 2015

Ranibizumab for vascularized pigment epithelium detachment in neovascular age-related macular degeneration: a retrospective analysis from the 12-month real-world TWIN study

Violaine Caillaux; Hassiba Oubraham; Salomon Y Cohen; Gérard Mimoun; Catherine Francais; Franck Fajnkuchen; Ghislaine Ducos de Lahitte; Stephanie Agnes Baillif; Laetitia Finzi; Eric H Souied

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5360. doi:

ARVO Annual Meeting Abstract June 2015

Retrospective analysis of patients with neovascular Age-related Macular Degeneration (nAMD) switched from ranibizumab to aflibercept and switched back to ranibizumab, using a treat and extend regimen .

Franck Rumen; Joel Uzzan; Hassiba Oubraham

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5361. doi:

ARVO Annual Meeting Abstract June 2015

Baseline characteristics of French patients with wet age-related macular degeneration (wAMD) enrolled in the LUMINOUS study.

Rocio Blanco-Garavito; Hassiba Oubraham; Benjamin Wolff; Salomon Y Cohen; Catherine P Garcher; Jean-Francois Korobelnik; Christian Delhay; Ramin Tadayoni; Audrey Derveloy; Eric H Souied; French LUMINOUS Group.

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5364. doi:

ARVO Annual Meeting Abstract June 2015

Profiles of wAMD patients associated with the number of intravitreal injection: a pooled analysis from the real-world LUMIERE &TWIN retrospective studies

Jean-Francois GIRMENS; Franck Fajnkuchen; Eric H Souied; Joel Uzzan; Gérard Mimoun; Violaine COLASSE-MARTHELOT; Audrey Derveloy; Hassiba Oubraham; Christian Delhay; Salomon Y Cohen

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1416. doi:

ARVO Annual Meeting Abstract April 2014

Grey hyper-reflective subretinal exudative lesions in wet age-related macular degeneration

Raphaelle Ores; Nathalie Puche; Giuseppe Querques; Rocio Blanco-Garavito; Benedicte Merle; Gabriel J Coscas; Hassiba Oubraham; Oudy Semoun; Eric H Souied

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):3406. doi:

ARVO Annual Meeting Abstract April 2014

Multimodal Imaging Of Ghosts In Geographic Atrophy Areas

Eric H Souied; Clemence Bonnet; Hassiba Oubraham; Rocio Blanco-Garavito; Nathalie Puche; Jennyfer Zerbib; Giuseppe Querques

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5886. doi:

ARVO Annual Meeting Abstract June 2013

TWIN : Evolution of visual acuity in patients with wet AMD diagnosed since 2010 and treated with ranibizumab, in current practice - Comparison with LUMIERE study

Hassiba Oubraham Mebroukine; Salomon Cohen; Gerard Mimoun; Eric Souied; Stéphane Quéré; Véronique Schneider; TWIN study group

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):3821. doi:

ARVO Annual Meeting Abstract April 2011

Lumiere: Evolution Of Visual Acuity In Patients With Wet AMD Treated With Ranibizumab, In Current Practice

Hassiba Oubraham; Salomon-Yves COHEN; Christian Malbrel; Gerard Mimoun; Alain Zourdani

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3533. doi:

NARROW

Content Type

Journal

Article Type

Specify Date Range

Long-term follow up or macular neovascularization using optical coherence tomography angiography: Pro Re Nata versus Treat&Extend regimens

OCT Angiography in the diagnosis and follow-up of retinal arterial macroaneurysms

Switching to aflibercept from ranibizumab in choroidal neovascularization related to angioid streaks: a multicenter real life study

Optical coherence tomography angiography visualizes morphological changes in choroidal neovascularization after anti-VEGF therapy: Monthly loading-phase versus Pro-Re-Nata regimen.

Real Life Use of Aflibercept In FraNce: oBservatiOnal study in Wet AMD: the RAINBOW study

Ranibizumab in patients with neovascular age-related macular degeneration in real-world clinical settings in France: 1-year data from the LUMINOUS™ study

Early and delayed visual acuity responders to ranibizumab in patients with neovascular age-related macular degeneration: a retrospective pooled analysis from the real-world LUMIERE and TWIN studies

Short-term results of the switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration

Anatomic and functional results of Vascularized Pigment Epithelial Detachment treatment with ranibizumab ( V-PED): One year follow-up of visual and anatomical outcomes

Ranibizumab for vascularized pigment epithelium detachment in neovascular age-related macular degeneration: a retrospective analysis from the 12-month real-world TWIN study

Retrospective analysis of patients with neovascular Age-related Macular Degeneration (nAMD) switched from ranibizumab to aflibercept and switched back to ranibizumab, using a treat and extend regimen .

Baseline characteristics of French patients with wet age-related macular degeneration (wAMD) enrolled in the LUMINOUS study.

Profiles of wAMD patients associated with the number of intravitreal injection: a pooled analysis from the real-world LUMIERE &TWIN retrospective studies

Grey hyper-reflective subretinal exudative lesions in wet age-related macular degeneration

Multimodal Imaging Of Ghosts In Geographic Atrophy Areas

TWIN : Evolution of visual acuity in patients with wet AMD diagnosed since 2010 and treated with ranibizumab, in current practice - Comparison with LUMIERE study

Lumiere: Evolution Of Visual Acuity In Patients With Wet AMD Treated With Ranibizumab, In Current Practice

To View More...

You must be signed into an individual account to use this feature.